JSJenna Stelmar

Jenna Stelmar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jenna Stelmar has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Gift of a Fresh Start: Results From A Single-Center Surgical Gift Program

    by Miriam Becker, Jenna Stelmar, Vanessa Natera, Gabriela Sendek, Andrea Yessaillian, Caitlyn Belza, Ricardo Rosales, Meera Reghunathan, Celene Nigro, Melissa Kanack, et al.

    Introduction: Since 1991, the Fresh Start Surgical Gifts Program (FSSGP) has provided surgical care to underserved patients at no direct cost. In 2009, the program transitioned from an outpatient center to a tertiary care hospital, offering complex surgical care 6 times per year with dedicated multidisciplinary teams. We describe a hybrid model for sustainable surgical care to low-income patients with unmet surgical needs. Methods: A retrospective chart review was conducted of all FSSGP patients at our children’s hospital from January 2009 to January 2023. Patient demographics and medical history were collected. Financial information captured total charges for housing, transportation, hospital, surgical costs, and gift-in-kind (GIK) donations, defined as the estimated market value of professional fees donated by all-volunteer clinical teams. Cost calculations used Medicare reimbursement rates tied to CPT codes, along with annually updated conversion factors and relative value units to account for inflation. Results: During the 14-year study period, 318 patients were treated: 44% from North America, 47% Central America, 3% South America, 3% Africa, and 3% Eastern Europe, South Asia, East Asia, and the Middle East combined. Of these 318 patients, 247 (78%) were treated by plastic surgery: 81% were treated for craniofacial conditions, 7% congenital hand conditions, 4% burn reconstruction, 5% breast conditions, 3% other congenital abnormalities, 2% oncologic reconstruction, and 2% trauma. Patients underwent an average of 3.0 surgeries (SD = 2.4; range = [1,16 surgeries]). The average total cost per patient was $110,837 (SD = $156,259; range = [$771, $1,212,044]). The average cost per surgical weekend was $179,586 and the average GIK per surgical weekend was $680,326. Conclusions: Our surgical gift model represents a sustainable, community-focused alternative to surgical mission trips.

  • Anatomic maps of erogenous and aversive sensation zones of the breasts, vulva, and vagina: a questionnaire-based study

    by Jenna Stelmar, Michael Zaliznyak, Sandeep Sandhu, Dylan Isaacson, Erin Duralde, Shannon M Smith, Gail A Knudson, Maurice M Garcia

    Background: Erogenous sensation zones (ESZs) elicit sexual pleasure upon stimulation. General ESZ maps exist, but they do not assess internal areas of the body, differentiate between individual structures, or quantify the importance of individual ESZs to sexual pleasure. Maps of aversive sensation zones (ASZs), or bodily areas individuals dislike having touched during sex, have not been described. Aim: To create detailed erogenous and aversive sensory maps of the vulva, vagina, and breasts, and assess the importance of each erogenous structure to sexual pleasure. Methods: An anonymous online questionnaire was administered to 441 sexually active cisgender women (mean age 48.9 ± 15.5 years) from March to June 2020 via Qualtrics. Respondents selected ESZs and ASZs from anatomic illustrations and rated each ESZ’s importance to their sexual pleasure. Respondents’ reasoning for choosing each ASZ was queried. Outcomes: Heat maps of ESZ and ASZ selection frequency, ESZ importance ratings, and ASZ reasoning. Results: More respondents selected ≧1 areas of the vulva as erogenous (82.0%), in comparison to the breasts (77.4%) and vagina (59.4%). The two most erogenous areas of the breast were also the most aversive: breast tissue (57.8% ESZ selection; 5.4% ASZ) and nipples (42.7%; 6.5%). Respondents most commonly reported these areas as aversive due to: “It’s overly sensitive” and “It hurts.” The most frequently selected ESZs of the vulva were the vaginal introitus (50.8%), periurethra (42.6%), and glans clitoris (41.3%). The top ASZs were the anus (34.0%) and perineum (7.9%), with primary reasons being: “It’s gross,” “It hurts,” and “I’m ashamed/embarrassed.” Of the five ESZs of the vagina, the superficial anterior (48.1%) and superficial posterior (32.9%) regions were the most selected. The cervix (6.8%), superficial posterior (5%), and deep posterior (3.4%) regions were the top ASZs due to “It hurts” and/or “It’s overly sensitive.” Clinical Implications: Erogenous and aversive sensory maps could help identify sexual concerns, inform preoperative counseling, and track sensory changes. Strengths and Limitations: This study captured detailed maps of internal and external ESZs and ASZs of the breasts, vulva, and vagina. Limitations include recall bias and inclusion of only cisgender women, rather than all people who share the same anatomy, irrespective of gender identity. Conclusions: Erogenous sensation was most prominent in the vulvar structures, including the vaginal introitus and glans clitoris, followed by the superficial surface of the vaginal canal. Aversive sensation associated with the anus primarily came from feelings of judgment and shame, while other ASZs were reportedly due to pain and sensitivity.


  • Open Access

    Endocrine, gender dysphoria, and sexual function benefits of gender-affirming bilateral orchiectomy: patient outcomes and surgical technique

    by Jenna Stelmar, Robert Victor, Nance Yuan, Shannon M Smith, Samhita Mallavarapu, Sandeep Sandhu, Maurice M Garcia

    Gender-affirming bilateral orchiectomy (GABO) may be completed as either a standalone procedure (sGABO) or at the same time as gender-affirming vaginoplasty (vGABO). GABO is postulated to decrease gender-affirming hormone therapy (GAHT) dosages and reduce gender dysphoria, but these phenomena are not empirically described in the medical literature. The primary aim of this study was to describe changes in GAHT dosages after sGABO and vGABO. A secondary aim was to assess sGABO patients’ preoperative decision-making priorities and postoperative satisfaction. A retrospective chart review identified 204 patients who completed GABO as either a standalone procedure (64% of patients) or at the same time as vaginoplasty (36%). Patient demographic data, surgical outcomes, and pre- and postoperative GAHT dosage data were recorded. Patients completed an opinion questionnaire to assessed decision-making priorities, as well as postoperative satisfaction and changes in quality-of-life measures. Primary outcomes included pre- and postoperative dosages of estradiol, progesterone, and spironolactone. Secondary outcomes included sGABO patient priorities, satisfaction with sGABO, changes in quality-of-life measures between sGABO and vGABO patients, and sGABO recommendations to future patients. The sGABO and vGABO patients experienced a statistically significant dosage reduction in all three GAHT assessed: estradiol, progesterone, and spironolactone (P < .05). All patients discontinued spironolactone postoperatively. Zero complications related to GABO were recorded for patients in either group. The patient questionnaire revealed that sGABO patients prioritize decreasing endogenous testosterone and reducing their GAHT as most important in their decision to undergo sGABO prior to vaginoplasty. A majority of sGABO patients reported improvement in all nine quality-of-life indices. None of the sGABO patients would recommend against sGABO to a friend who is waiting for vaginoplasty. For patients who are interested in vaginoplasty, sGABO may serve as a more immediate, low-risk, intermediary step that comes with the benefits of GABO, including significant GAHT medication reduction and gender dysphoria relief. This study offers a comprehensive evaluation of the impact of GABO on patients, combining empirical data with subjective patient feedback. Limitations include the retrospective design and the use of unvalidated survey questions. Prevaginoplasty GABO is a viable option to more immediately alleviate gender dysphoria and reduce GAHT medications for patients who are interested in gender-affirming vaginoplasty.